scholarly journals SAFETY AND TOLERABILITY OF VILDAGLIPTIN IN CLINICAL PRACTICE: NEWER PROMISING GLIPTIN FOR TYPE 2 DIABETES MELLITUS

2021 ◽  
Vol 9 (1) ◽  
Author(s):  
Shaik Kareemulla ◽  
B. Himabindu ◽  
D. Sheklane Khan ◽  
G. Ramu ◽  
S. Mahammed Rafi
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Combination Therapy ◽  
Severe Renal Impairment ◽  
The Elderly ◽  
Hypoglycemic Agents ◽  
Oral Hypoglycemic Agents ◽  
Dipeptidyl Peptidase 4

The prevalence of type 2 diabetes (T2DM) increases with age. Older patients have an increased likelihood for T2DM-related morbidity and mortality. The dipeptidyl peptidase-4 inhibitor vildagliptin is approved for use as monotherapy and combination therapy in type 2 diabetes mellitus. This article reviews the clinical efficacy and tolerability of vildagliptin in the treatment of type 2 diabetes, as well as summarizing its pharmacological properties. Improvements in glycaemic control were also seen with vildagliptin in elderly patients with type 2 diabetes and in patients with type 2 diabetes and moderate or severe renal impairment. Vildagliptin was generally well tolerated in patients with type 2 diabetes, was weight neutral and was associated with a low risk of hypoglycemia, reflecting its glucose-dependent mechanism of action. The elderly population with T2DM poses unique treatment challenges and have not been particularly well-represented in clinical trials, highlighting the need for additional studies to better define appropriate glucose targets and to ascertain the best strategies for achieving and maintaining appropriate glycaemic levels. In conclusion, vildagliptin is an important option for use in combination with metformin, a sulfonylurea or a thiazolidinedione in patients with type 2 diabetes who require combination therapy. Keywords: DPP-4 inhibitors, Elderly, Oral hypoglycemic agents, Type 2 diabetes, Vildagliptin

scholarly journals Combination Therapy of Oral Hypoglycemic Agents in Patients with Type 2 Diabetes Mellitus

2017 ◽  
Vol 41 (5) ◽  
pp. 357 ◽  
Author(s):  
Min Kyong Moon ◽  
Kyu-Yeon Hur ◽  
Seung-Hyun Ko ◽  
Seok-O Park ◽  
Byung-Wan Lee ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Combination Therapy ◽  
Hypoglycemic Agents ◽  
Oral Hypoglycemic Agents

scholarly journals Combination therapy of oral hypoglycemic agents in patients with type 2 diabetes mellitus

2017 ◽  
Vol 32 (6) ◽  
pp. 974-983 ◽  
Author(s):  
Min Kyong Moon ◽  
Kyu Yeon Hur ◽  
Seung-Hyun Ko ◽  
Seok-O Park ◽  
Byung-Wan Lee ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Combination Therapy ◽  
Hypoglycemic Agents ◽  
Oral Hypoglycemic Agents

scholarly journals The importance and advantages of the timely prescription of insulin to the patients with type 2 diabetes mellitus

2012 ◽  
Vol 58 (3) ◽  
pp. 56-60
Author(s):  
I R Iarek-Martynova
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Insulin Therapy ◽  
Clinical Situation ◽  
Hypoglycemic Agents ◽  
Negative Consequences ◽  
Oral Hypoglycemic Agents ◽  
Adequate Treatment

The onset of insulin therapy is an important stage in the treatment of type 2 diabetes mellitus. Its timely beginning ensures better control of glycemia and reduces the negative consequences of chronic glucose cytotoxicity and lipotoxicity. The achievement and maintenance of the stable compensation of the disease are the indispensable conditions for successful prophylaxis and adequate treatment of chronic complications of diabetes mellitus. The ADA guidelines recommend to initiate insulin therapy at the early stages of the disease provided it is dictated by the clinical situation or combine it with the use of oral hypoglycemic agents if the targeted HbA1c levels fail to be reached despite the intake of one or more tableted preparations.

Efficacy and safety of empagliflozin in combination with other oral hypoglycemic agents in patients with type 2 diabetes mellitus

2016 ◽  
Vol 63 (10) ◽  
pp. 519-526
Author(s):  
Irene Romera ◽  
Francisco Javier Ampudia-Blasco ◽  
Antonio Pérez ◽  
Bernat Ariño ◽  
Egon Pfarr ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Hypoglycemic Agents ◽  
Efficacy And Safety ◽  
Oral Hypoglycemic Agents

DPP-4 inhibitors and hypoglycemia in the patients with type 2 diabetes mellitus

2013 ◽  
Vol 59 (5) ◽  
pp. 72-80
Author(s):  
Iu Sh Khalimov
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Adverse Events ◽  
Clinical Condition ◽  
Hypoglycemic Agents ◽  
The Novel ◽  
Oral Hypoglycemic Agents ◽  
Novel Approaches

The incidence of hypoglycemia remains rather high among the population of patients with type 2 diabetes mellitus (DM2) especially in those treated with the traditional oral hypoglycemic agents. Hypoglycemia is one of the most frequent adverse events encountered by a physician dealing with diabetic (DM2) patients. At the same time, the novel approaches are currently available that allow this clinical condition to be avoided.

Sign in / Sign up

Export Citation Format

Share Document